ACUR · As filed with the SEC
Acura Pharmaceuticals cash flow statement, by fiscal year
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands
| USD thousands | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 | FY2017 Year ended Dec 31, 2017 | FY2016 Year ended Dec 31, 2016 | FY2015 Year ended Dec 31, 2015 | FY2014 Year ended Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|
| Cash Flows from Operating Activities: | ||||||||
| Net loss | — | (1,208,000) | (3,774,000) | (3,842,000) | (5,682,000) | (7,388,000) | (4,989,000) | (13,209,000) |
| Net loss | (879,000) | — | — | — | — | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | — | — | — | — | 87 | 138 | 125 | 119 |
| Provision to reduce inventory to net realizable value | — | — | — | — | 0 | 26 | 330 | 201 |
| Depreciation | 47,000 | 56,000 | 66,000 | 73,000 | — | — | — | — |
| Provision for sales returns | — | — | — | 0 | 49,000 | 99,000 | 267,000 | — |
| Provision for fixed asset impairment | — | — | — | — | 0 | 82 | — | — |
| Non-cash stock-based compensation | 58,000 | 36,000 | 108,000 | 218,000 | 464,000 | 588,000 | 606,000 | 890,000 |
| Capitalized debt discount | — | — | (13,000) | (172,000) | — | — | — | — |
| Amortization of debt discount and deferred debt issue costs | — | — | 66,000 | 87,000 | 99,000 | 145,000 | 186,000 | 188,000 |
| Amortization of bond premium in marketable securities | — | — | — | — | 0 | 31 | 127 | 250 |
| Amortization of intangible asset | 26,000 | 69,000 | 207,000 | 207,000 | 207,000 | 207,000 | 207,000 | 155,000 |
| Loss on debt extinguishment | — | — | 2,600,000 | (296,000) | — | — | — | — |
| Amortization of right of use asset | 17,000 | — | — | — | — | — | — | — |
| Impairment charge on intangible asset | 47,000 | 668,000 | — | — | — | — | — | — |
| Loss on disposal of equipment | — | — | 1,000 | 0 | (2,000) | 1,000 | 19,000 | 0 |
| (Gain) on sales of marketable securities | — | — | — | — | 0 | (2) | (3) | (4) |
| Sales return liability | 0 | (223,000) | — | (31,000) | (99,000) | — | — | — |
| Gains on forgiveness of loans under CARES Act | (535,000) | — | — | — | — | — | — | — |
| Changes in assets and liabilities: | ||||||||
| Trade accounts receivable | — | — | — | 0 | 23,000 | 19,000 | (69,000) | 118,000 |
| Royalty receivable | 0 | 52,000 | 55,000 | (66,000) | (21,000) | (45,000) | — | — |
| Accrued investment income | — | — | — | — | 0 | 37 | 29 | 54 |
| Inventories | — | — | — | 0 | 103,000 | (59,000) | (302,000) | (254,000) |
| Collaboration revenue receivable from related party | 119,000 | (119,000) | (78,000) | 0 | 79,000 | (43,000) | — | — |
| License fee receivable from related party | 350,000 | (400,000) | — | — | — | — | — | — |
| Prepaid expenses and other current assets | (10,000) | (17,000) | 44,000 | 109,000 | (7,000) | 149,000 | 54,000 | 158,000 |
| Other current deferred assets | — | — | — | — | — | 0 | 218 | (32) |
| Income taxes refundable | — | 68,000 | — | — | — | — | — | — |
| Income taxes refundable | 0 | — | 67,000 | 0 | (135,000) | — | — | 0 |
| Other assets | — | — | — | — | 0 | 175 | (175) | 5 |
| Accounts payable | 161,000 | (206,000) | (368,000) | 602,000 | (74,000) | (33,000) | (107,000) | (57,000) |
| Accrued expenses | (394,000) | 46,000 | (11,000) | (343,000) | 236,000 | 139,000 | (4,000) | 27,000 |
| Deferred revenue | — | — | — | — | — | 0 | (353) | 66 |
| Accrued interest on loan | — | — | — | (566,000) | 141,000 | 172,000 | 127,000 | 260,000 |
| Other current and non-current liabilities | — | — | — | — | — | — | 19 | 21 |
| Accrued interest on related party loans | 199,000 | 449,000 | 394,000 | 110,000 | — | — | — | — |
| Other current liabilities | 52,000 | 10,000 | 18,000 | 2,000 | 22,000 | (1,000) | — | — |
| Net cash used in operating activities | — | — | — | — | — | (5,563) | (3,688) | (11,044) |
| Purchases of marketable securities | — | — | — | — | — | 0 | (3,522) | (2,203) |
| Net cash used in operating activities | (742,000) | (719,000) | (618,000) | (3,908,000) | (4,510,000) | — | — | — |
| Proceeds from sales and maturities of marketable securities | — | — | — | — | 0 | 10,873 | 3,830 | 4,336 |
| Acquisition of product rights | — | — | — | — | — | — | 0 | (2,000) |
| Proceeds from transfer of equipment to licensee | — | — | — | 0 | 103,000 | 0 | 14,000 | — |
| Net cash provided by investing activities | — | — | — | — | — | 10,798 | 108 | (2) |
| Proceeds from transfer of inventory to licensee | — | — | — | — | 206 | 0 | 225 | 0 |
| Proceeds from Registered Direct offering | — | — | — | — | — | 0 | 7,636 | — |
| Transaction costs from ATM offering | — | — | — | — | — | 0 | (611) | 0 |
| Transaction costs from Registered Direct offering | — | — | — | — | — | 0 | — | — |
| Capital expenditures | — | — | — | — | 0 | (75) | (214) | (135) |
| Proceeds from transfer of inventory to licensee | — | — | — | 0 | — | — | — | — |
| Net cash provided by investing activities | — | — | — | 0 | 309,000 | — | — | — |
| Cash Flows from Financing Activities: | ||||||||
| Proceeds from exercise of stock options | — | — | — | — | — | — | 0 | 8 |
| Proceeds from distribution of restricted stock units | — | — | — | — | 0 | 1 | 1 | 1 |
| Proceeds from distribution of RSU awards | 3,000 | 3,000 | 14,000 | 2,000 | — | — | — | — |
| Statutory minimum payroll withholding taxes paid on the distribution of shares pursuant to RSU awards | (8,000) | (2,000) | — | — | — | — | 0 | (529,000) |
| Long-term debt borrowings | — | — | — | — | — | — | — | 0 |
| Capitalized debt issuance costs | — | — | — | — | — | — | — | 0 |
| Proceeds from loan under CARES Act | 266,000 | 269,000 | — | — | — | — | — | — |
| Proceeds from issuance of promissory note to related party | 150,000 | — | 1,375,000 | 4,350,000 | — | — | — | — |
| Principal payments loan | — | — | — | (2,573,000) | (2,760,000) | (2,540,000) | (1,960,000) | — |
| Net cash (used in) provided by financing activities | — | — | — | — | — | (2,539) | 5,291 | (520) |
| Issuance of common stock | — | — | — | 0 | 4,000,000 | — | — | — |
| Payments on finance lease | (17,000) | — | — | — | — | — | — | — |
| Net cash provided by financing activities | 394,000 | 270,000 | 1,389,000 | 1,779,000 | 1,240,000 | — | — | — |
| Net (decrease) increase in cash and cash equivalents | — | — | — | — | (2,961) | 2,696 | 1,711 | (11,566) |
| Cash and cash equivalents at beginning of year | — | — | — | — | 5,181 | 2,485 | — | — |
| Cash and cash equivalents at end of year | — | — | — | — | — | 5,181 | — | — |
| Cash and cash equivalents at beginning of year | — | — | — | 2,220 | 2,681 | 2,485 | 774 | 12,340 |
| Cash and cash equivalents at end of year | — | — | — | — | 2,220 | — | 2,485 | 774 |
| Net decrease in cash | (348,000) | (449,000) | 771,000 | (2,129,000) | — | — | — | — |
| Cash at beginning of period | 413,000 | 862,000 | 91,000 | 2,220,000 | — | — | — | — |
| Cash at end of end of period | 65,000 | 413,000 | 862,000 | 91,000 | — | — | — | — |
| Supplemental Disclosures of Cash Flow Information: | ||||||||
| Interest on term loan with Oxford Finance LLC | — | — | — | — | — | 576 | 844 | 765 |
| Cash interest payments on loans | 0 | — | — | 759,000 | 355,000 | — | — | — |
| Income taxes, net of refunds | — | — | — | — | 0 | 0 | 0 | 14 |
| Cash paid for income taxes | 0 | — | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.